RNAC vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 18, 2026

RNAC

41.9
AI Score
VS
RNAC Wins

CBIO

40.1
AI Score

Investment Advisor Scores

RNAC

42score
Recommendation
HOLD

CBIO

40score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RNAC CBIO Winner
Revenue 78,000 1.04M CBIO
Net Income -23.41M -48.12M RNAC
Net Margin -30016.7% -4631.4% CBIO
Operating Income -55.65M -51.09M CBIO
ROE 18.7% -29.5% RNAC
ROA -7.3% -26.3% RNAC
Total Assets 318.63M 182.76M RNAC
Cash 147.61M 171.59M CBIO
Current Ratio 7.48 9.66 CBIO
Free Cash Flow -43.52M -28.56M CBIO

Relative Price Performance (Last 90 Days)

RNAC 1M: -22.4% · 3M: -31.8% CBIO 1M: -20.5% · 3M: -16.6%

Current Technical Phase

RNAC

Markdown
Sell / avoid

Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 28

RSI (14): 28.0 · Price: $7.22

CBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 35

RSI (14): 35.1 · Price: $14.26

Fundamentals Snapshot

Metric RNAC CBIO
Market Cap — —
Forward P/E -1.9 -5.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.9% 0.0%
Gross Margin -45.3% 1.0%
Operating Margin -66.8% -14.3%
EPS -5.78 -0.14
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RNAC is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.